pentobarbital will lessen the extent or outcome of fosphenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Warning/Monitor.Avoid; coadministration with CYP3A inducers may well lead to diminished plasma concentrations of elvitegravir and/or even a concomitantly administered protease inhibitor and produce loss of therapeutic influence also